These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36920307)

  • 41. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).
    Hirose K; Inukai T; Kikuchi J; Furukawa Y; Ikawa T; Kawamoto H; Oram SH; Göttgens B; Kiyokawa N; Miyagawa Y; Okita H; Akahane K; Zhang X; Kuroda I; Honna H; Kagami K; Goi K; Kurosawa H; Look AT; Matsui H; Inaba T; Sugita K
    Blood; 2010 Aug; 116(6):962-70. PubMed ID: 20519628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The LMO2 oncogene regulates DNA replication in hematopoietic cells.
    Sincennes MC; Humbert M; Grondin B; Lisi V; Veiga DF; Haman A; Cazaux C; Mashtalir N; Affar el B; Verreault A; Hoang T
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1393-8. PubMed ID: 26764384
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.
    Appert A; Nam CH; Lobato N; Priego E; Miguel RN; Blundell T; Drynan L; Sewell H; Tanaka T; Rabbitts T
    Cancer Res; 2009 Jun; 69(11):4784-90. PubMed ID: 19487290
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2.
    Fleskens V; Mokry M; van der Leun AM; Huppelschoten S; Pals CE; Peeters J; Coenen S; Cardoso BA; Barata JT; van Loosdregt J; Coffer PJ
    Oncogene; 2016 Aug; 35(31):4141-8. PubMed ID: 26686090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1.
    Lu L; Wang J; Fang F; Guo A; Jiang S; Tao Y; Zhang Y; Li Y; Zhang K; Zhang Z; Zhuo R; Chu X; Li X; Tian Y; Ma L; Sang X; Chen Y; Yu J; Yang Y; Cao H; Gao J; Lu J; Hu S; Pan J; He H
    Cell Death Dis; 2023 Aug; 14(8):518. PubMed ID: 37573405
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice.
    O'Neil J; Billa M; Oikemus S; Kelliher M
    Oncogene; 2001 Jun; 20(29):3897-905. PubMed ID: 11439353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Expression of microRNA-223 in lymphocytic leukemia cells and its action mechanism].
    Nan Z; Liang Y; Fu R; Liu H; Ruan EB; Wang XM; Wang GJ; Qu W; Liu H; Wu YH; Song J; Xing LM; Guan J; Li LJ; Wang HQ; Shao ZH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):556-61. PubMed ID: 23815897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.
    Larson RC; Lavenir I; Larson TA; Baer R; Warren AJ; Wadman I; Nottage K; Rabbitts TH
    EMBO J; 1996 Mar; 15(5):1021-7. PubMed ID: 8605871
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model.
    Pais H; Ruggero K; Zhang J; Al-Assar O; Bery N; Bhuller R; Weston V; Kearns PR; Mecucci C; Miller A; Rabbitts TH
    Sci Rep; 2019 Apr; 9(1):5760. PubMed ID: 30962539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.
    Liu Y; Huang D; Wang Z; Wu C; Zhang Z; Wang D; Li Z; Zhu T; Yang S; Sun W
    Sci Rep; 2016 Oct; 6():36050. PubMed ID: 27779255
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.
    Agostinelli C; Paterson JC; Gupta R; Righi S; Sandri F; Piccaluga PP; Bacci F; Sabattini E; Pileri SA; Marafioti T
    Histopathology; 2012 Jul; 61(1):33-46. PubMed ID: 22394247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FoxN1-dependent thymic epithelial cells promote T-cell leukemia development.
    Ghezzo MN; Fernandes MT; Pacheco-Leyva I; Rodrigues PM; Machado RS; Araújo MAS; Kalathur RK; Futschik ME; Alves NL; Dos Santos NR
    Carcinogenesis; 2018 Dec; 39(12):1463-1476. PubMed ID: 30256907
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.
    Mansour MR; Sanda T; Lawton LN; Li X; Kreslavsky T; Novina CD; Brand M; Gutierrez A; Kelliher MA; Jamieson CH; von Boehmer H; Young RA; Look AT
    J Exp Med; 2013 Jul; 210(8):1545-57. PubMed ID: 23857984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
    Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
    Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.
    Malumbres R; Fresquet V; Roman-Gomez J; Bobadilla M; Robles EF; Altobelli GG; Calasanz MJ; Smeland EB; Aznar MA; Agirre X; Martin-Palanco V; Prosper F; Lossos IS; Martinez-Climent JA
    Haematologica; 2011 Jul; 96(7):980-6. PubMed ID: 21459790
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes.
    Zhou S; Fatima S; Ma Z; Wang YD; Lu T; Janke LJ; Du Y; Sorrentino BP
    Mol Ther; 2016 Jun; 24(6):1090-1099. PubMed ID: 26957223
    [TBL] [Abstract][Full Text] [Related]  

  • 57. LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling.
    Liu Y; Wang Z; Huang D; Wu C; Li H; Zhang X; Meng B; Li Z; Zhu T; Yang S; Sun W
    Oncotarget; 2017 Feb; 8(6):9513-9524. PubMed ID: 27880729
    [TBL] [Abstract][Full Text] [Related]  

  • 58. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.
    Tremblay CS; Saw J; Boyle JA; Haigh K; Litalien V; McCalmont H; Evans K; Lock RB; Jane SM; Haigh JJ; Curtis DJ
    Blood; 2023 Jul; 142(3):274-289. PubMed ID: 36989489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic and epigenetic determinants mediate proneness of oncogene breakpoint sites for involvement in TCR translocations.
    Larmonie NS; van der Spek A; Bogers AJ; van Dongen JJ; Langerak AW
    Genes Immun; 2014 Mar; 15(2):72-81. PubMed ID: 24304972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monoallelic
    Veiga DFT; Tremblay M; Gerby B; Herblot S; Haman A; Gendron P; Lemieux S; Zúñiga-Pflücker JC; Hébert J; Cohen JP; Hoang T
    Front Immunol; 2022; 13():867443. PubMed ID: 35401501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.